Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Jefferies 2013 Global Healthcare Conference

34 slides from Sucampo Pharmaceuticals's conference presentation, Jun 6, 2013

  1. Slide 1: Jefferies 2013 Global Healthcare Conference: Sucampo Corporate Update

    Slide 1: Jefferies 2013 Global Healthcare Conference: Sucampo Corporate Update

    Jefferies 2013 Global Healthcare Conference Sucampo Pharmaceuticals, Inc. Corporate Update Cary Claiborne, Chief Financial Officer June 6, 2013

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set fo

  3. Slide 3: Commercial-stage, global biopharmaceutical company

    Slide 3: Commercial-stage, global biopharmaceutical company

    Commercial-stage, global biopharmaceutical company • 2 FDA-approved drugs based on our proprietary prostone technology • AMITIZA® (lubiprostone) in gastroenterology • Approved for chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipati

  4. Slide 4: Only company developing and commercializing prostone compounds globally

    Slide 4: Only company developing and commercializing prostone compounds globally

    Sucampo is the only company developing and commercializing prostone compounds globally • Prostones: • Functional fatty acids naturally occuring in the human body • Selective ion-channel activators • Physiological mediators of restoration of cellular homeostasis and tissue regeneration • Clinical saf

  5. Slide 5: Proprietary Platform Technology: Prostones are Highly Potent Ion-Channel Activators

    Slide 5: Proprietary Platform Technology: Prostones are Highly Potent Ion-Channel Activators

    Proprietary Platform Technology: Sucampos Prostones are Highly Potent Ion-Channel Activators AMITIZA RESCULA Fluid Secretion ClC-2-Chloride Channel Activation BK-Potassium Channel Activation Smooth Muscle Relaxation Barrier Repair and Mucosal Protection Anti-Inflammatory Activity See Reference 1 Ner

  6. Slide 6: Global AMITIZA Approvals and Regulatory Filings

    Slide 6: Global AMITIZA Approvals and Regulatory Filings

    Global AMITIZA Approvals and Regulatory FilingsJapanCC (2012)UKCIC (2012)OIC (filed)USCIC (2006)IBS-C (2008)OIC Approved(April 2013)SwitzerlandCIC (2009)OIC (filed)AMITIZA has been used for >7 y with 7M prescriptions by patients suffering from CIC and IBS-C 6

  7. Slide 7: Leader in Gastroenterology with Three Approved Indications for AMITIZA

    Slide 7: Leader in Gastroenterology with Three Approved Indications for AMITIZA

    Sucampo: Leader in Gastroenterology with Three Approved Indications for AMITIZA • CIC CIC affects ~14%−16%2,3 and IBS-C affects ~5% of adult population globally4 CIC accounts for 92,000 hospitalizations/yr in US5 IBS-C Patients with IBS consume >50% more healthcare resources than those without IBS6

  8. Slide 8: AMITIZA US: OIC approval and strong YoY growth

    Slide 8: AMITIZA US: OIC approval and strong YoY growth

    AMITIZA US • OIC indication approved in April 2013 Priority review for first and only medicine for the treatment of OIC in adults with chronic, non-cancer pain $10M milestone payment received Partner Takeda’s reps began selling week of May 13 Strategy to build awareness that AMITIZA is the first and

  9. Slide 9: AMITIZA US OIC Launch: Build on Strengths

    Slide 9: AMITIZA US OIC Launch: Build on Strengths

    Heritage AMITIZA 74.7 67.7 Relieves Bloating/Discomfort 72.2 61.8 71.5 62.4 64.1 57.8 Build on Strength Build on Strength in Efficacy12 Pregnancy warning removed from label AMITIZA US OIC Launch: Build on Strengths and 7M prescriptions over 7 years MiraLax Provides Sustained Relief Relieves Abdomina

  10. Slide 10: Strategy to Grow AMITIZA

    Slide 10: Strategy to Grow AMITIZA

    Strategy to Grow AMITIZA Target Goal PCPs who already write AMITIZA +OICPain Specialists GIs +CIC +IBS-C +OIC Target Goal PCP Non-Writers 10

  11. Slide 11: Competitive Landscape

    Slide 11: Competitive Landscape

    Competitive Landscape EXPECT NO MARKET CHALLENGE FOR AMITIZA USE FOR OIC NON-CANCER PATIENTS FOR UP TO 2 YEARS Bevenopran Adolor/Cubist Phase 3Phase 2 Marketed Naloxone Naloxegol AstraZeneca/Nektar Relistor (PO) Progenics/SalixTheravance/ GlaxoSmithKline AMITIZA Filed Relistor (SC) Progenics/Salix S

  12. Slide 12: AMITIZA launch in the UK and Switzerland

    Slide 12: AMITIZA launch in the UK and Switzerland

    • First-ever prescription medicine approved for chronic constipation • All launch metrics have been surpassed: revenue and patient numbers tracking above expectation • Sucampo recorded $2.2M of product sales revenue in Q1, double our internal forecast • Initiated NICE endorsement process in UK follo

  13. Slide 13: Glaucoma unmet needs

    Slide 13: Glaucoma unmet needs

    • Glaucoma is age-related and the second leading cause of bilateral blindness worldwide; will affect an estimated 79.6M people worldwide by 202013 • Reduction in intra-ocular pressure (IOP) is currently the only modifiable risk factor for patients with glaucoma and ocular hypertension13 • Compliance

  14. Slide 14: RESCULA offers an alternate route to IOP reduction

    Slide 14: RESCULA offers an alternate route to IOP reduction

    • Primary Open Angle Glaucoma / Ocular Hypertension market has unmet needs • RESCULA offers an alternate route to IOP reduction -the strength of RESCULA is its safety and tolerability profile • RESCULA will have a competitive share of voice

  15. Slide 15: Open Angle Glaucoma patient population and market

    Slide 15: Open Angle Glaucoma patient population and market

    • 2.2M people affected by Open Angle Glaucoma17 • Projected to grow to 3.4M by 2020 due to aging population17 • Additional 3-6M patients with Ocular Hypertension18 • ~$2B: US sales volume (2012)19 and ~$1B: Japan sales volume (2011)1 TRx Volume 2.7M 2.6M 2.5M 2.4M 2.3M 2.2M 2.1M 2.0M Month

  16. Slide 16: Aging population and glaucoma risk

    Slide 16: Aging population and glaucoma risk

    More than 11M Americans are = 80 years of age20 Age is an independent risk factor for glaucoma17 Elderly patients generally have greater susceptibility to the systemic adverse effects of glaucoma medications21,22 Population (M) 40 32.5M 27.6M 20 10 0 30 2000 2010 2020 2030 2040 2050 Projected Growth

  17. Slide 17: First-line glaucoma therapy choices

    Slide 17: First-line glaucoma therapy choices

    • Reasonable choices for 1st line therapy include8: • Prostaglandin analogs • Beta-blockers • Alpha agonists 23.8% • Topical CAIs • st line for most patients • Efficacy • Beta-blockers are well-tolerated

  18. Slide 18: RESCULA mechanism and profile

    Slide 18: RESCULA mechanism and profile

    Believed to reduce elevated IOP by increasing the outflow of aqueous humor through the trabecular meshwork via BK channel activation • A prostone, not a prostaglandin analog • Should be considered when systemic and/or ocular side effects are a concern: • Effective at lowering IOP throughout the day

  19. Slide 19: RESCULA launch progress and managed care

    Slide 19: RESCULA launch progress and managed care

    • systemic side effects • Positive feedback and significant progress • Efforts focused on ophthalmologists and optometrists • More than 19,000+ calls have already been made • Over 78,000 samples have been shipped • Expect sales to increase in 2H • Aggressively pursuing managed care coverage for RESC

  20. Slide 20: Sucampo's Clinical Pipeline and Product

    Slide 20: Sucampo's Clinical Pipeline and Product

    CLINICAL FOCUS PHASE 1 Launched 1Q13 Launched 2Q13 Filed 1Q13 AMITIZA Pediatric Constipation FPFV 2H13 Launched 1Q13 Japan/US* 1Q13 4Q13 1Q13 4Q12 Development STAGE OF CLINICAL DEVELOPMENT COMPOUNDS DISCOVERY PRECLINICAL PHASE 2 PHASE 3 FILING AMITIZA CIC UK/CH AMITIZA OIC US AMITIZA OIC UK/CH RESCU

  21. Slide 21: Key Facts

    Slide 21: Key Facts

    $8.48, Shares Outstanding (03-31-13) 229,661 Market Capitalization (06-03-13) $358.5M Debt (03-31-13) $62.5M $95.8M $325.1M Full-time Employees (06-03-13) Accounting Firm PricewaterhouseCoopers LLP Key Facts Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD Stock Price (06-03-13), 52-

  22. Slide 22: Q1 2013 Financial Highlights

    Slide 22: Q1 2013 Financial Highlights

    $60.7 $64.9 $10.9 $14.4 $16.9 +7%+7%+17% Q1-12 Q1-13 Q1-12 Q1-13 Q1-13 $M Q1 2013 Financial Highlights $11.7 Q1-12 Total Revenues Product Royalty AMITIZA Net Sales Revenue

  23. Slide 23: Key Value Drivers

    Slide 23: Key Value Drivers

    US AMITIZA Japan EU US Pipeline Cobiprostone SPI-017 Global Launch: Q1 2013 Complete spinal stenosis P2A trial: Q4 2013 / territories 2013 available in UK for CIC 2013 Key Value Drivers RESCULA Obtain approval of OIC sNDA: Q2 2013 $10M milestone payment upon first OIC sale Achieve FPFV

  24. Slide 24: The Science of Innovation

    Slide 24: The Science of Innovation

    $sucampo — * The Science of Innovation

  25. Slide 25: Terms of Sucampo's AMITIZA Agreements

    Slide 25: Terms of Sucampo's AMITIZA Agreements

    Terms of Sucampo’s AMITIZA Agreements • Takeda Agreement Takeda shall promote, market, and sell AMITIZA in US and Canada Sucampo’s tiered royalty rate: 18%−26% of annual net sales Sucampo earned $20M in upfront and $130M in development milestone payments as of 03/31/13 Sucampo received $10M mileston

  26. Slide 26: Abdominal Pain Improvement in IBS-C Patients

    Slide 26: Abdominal Pain Improvement in IBS-C Patients

    Substantial Abdominal Pain Improvement in IBS-C Pati ents Reporting at Least Severe Abdominal Pain at Baseline* % Improvement Placebo BID (n = 94) Lubiprostone 8 μg BID (n = 183) P † ≥10 53.9% 61.9% <0.0001 ≥20 40.1% 49.6% <0.0001 ≥30 24.2% 35.1% <0.0001 ≥40 14.5% 23.7% <0.0001 ≥50 9.4% 16.7% <0.000

  27. Slide 27: Long-term Efficacy in IBS-C

    Slide 27: Long-term Efficacy in IBS-C

    Long-term Efficacy μg BID in IBS-C Positive Long-term Treatment Response: Phase 3 Studies of AMITIZA 840 35 30 25 20 15 10 5 0 1 2 3 4 5 6 7 8 9101112 Month See Reference 1 Treatment Responders, % 27

  28. Slide 28: Overall SBM Response in OIC Patients

    Slide 28: Overall SBM Response in OIC Patients

    Overall Spontaneous Bowel Movement (“SBM”) Response in OIC Patients Proportion of Responders, %30 25 20 18.9 15.4 27.1 24.3 P = 0.03* = 8.2 = 8.9 Placebo 15 Lubiprostone 10 5 0 Study 1 Study 2 n = 431 n = 418 *Statistically significant (P ≤0.05) See Reference 29 28

  29. Slide 29: AMITIZA Intellectual Property

    Slide 29: AMITIZA Intellectual Property

    AMITIZA Intellectual Property • AMITIZA has a robust patent estate Latest patents expire in 2027 Paragraph IV certification notice letter to Sucampo received on January 2, 2013 regarding ANDA submitted to FDA by Anchen Pharmaceuticals Notice letter alleges AMITIZA’s composition, method of use, and/o

  30. Slide 30: Issued Lubiprostone Patents (US)

    Slide 30: Issued Lubiprostone Patents (US)

    Issued Lubiprostone Patents US Patent No. Expires Type of Patent 5,284,858 2014 Composition of matter (drug substance) 6,414,016 2020 Therapeutic use (treating constipation) 6,583,174 2020 Composition of matter (drug product) 6,982,283 2022 Therapeutic use (treating OIC) 7,064,148 2022 Therapeutic u

  31. Slide 31: Issued Lubiprostone Patents (Japan and Europe)

    Slide 31: Issued Lubiprostone Patents (Japan and Europe)

    Issued Lubiprostone Patents Japanese Patent No. Expires Type of Patent 4,332,316 2023 Composition of matter (drug substance) 4,332,353 2022 Therapeutic use (treating OIC) 4,684,334 2023 Therapeutic use (treating constipation) 4,783,794 2028 Composition of matter (drug product) 4,786,866 2023 Therape

  32. Slide 32: Issued Unoprostone Isopropyl Patents

    Slide 32: Issued Unoprostone Isopropyl Patents

    Issued Unoprostone Isopropyl Patents US Patent No. Expires Type of Patent 6,770,675 2018 Composition of matter (drug product) and therapeutic use (treating ocular hypertension) 6,458,836 2021 Therapeutic use (treating ocular hypertension and glaucoma) *For Orange Book-listed patents concerning unopr

  33. Slide 33: References

    Slide 33: References

    References 1. Sucampo data on file. 2. Suares et al. Am J Gastroenterol. 2011 3. Kantar Health Epi database http://epidb.khapps.jp 4. Saito et al. Am J Gastroenterol. 2002 5. Lembo et al. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 2010 6. Hulisz D. J Manag Care Pharm. 2004 7. Salm

  34. Slide 34: References (cont'd)

    Slide 34: References (cont'd)

    References (cont’d) 21. American Academy of Ophthalmology Glaucoma Basic and Clinical Science Course 2012-2013 22. US Census Bureau The Older Population: 2010 (November 2011) 23. Kaiserman I et al. Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res. 2009 Jul;34(7):517-22. 24. Based

Source: SEC EDGAR · 8-K filed Jun 6, 2013

More decks from Sucampo Pharmaceuticals Inc